MILGa-01: A first in human study to evaluate the safety and tolerability of monoclonal antibody conjugate MILGa (MIL-38/Gallium67) in patients with advanced prostate, bladder and pancreatic cancer.

Trial Profile

MILGa-01: A first in human study to evaluate the safety and tolerability of monoclonal antibody conjugate MILGa (MIL-38/Gallium67) in patients with advanced prostate, bladder and pancreatic cancer.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs MILGa (Primary)
  • Indications Bladder cancer; Pancreatic cancer; Prostate cancer
  • Focus Adverse reactions; First in man
  • Acronyms MILGa-01
  • Sponsors Minomic International
  • Most Recent Events

    • 28 Jun 2017 According to a Minomic International media release, the first half of the study dosed two patients with pancreatic cancer and four with prostate cancer.
    • 28 Jun 2017 According to a Minomic International media release, independent Drug Safety Monitoring Committee has formally approved the continuation of the clinical trial to the final six of twelve subjects.
    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top